Skip to main content

Table 2 Baseline characteristics among breast cancer subtypes, n(%)

From: Integration of breast cancer care in a middle-income country: learning from Suandok Breast Cancer Network (SBCN)

Variables

Total

Cohort 1

Cohort 2

P-valuea

Number of patients

3868

1485

2383

Age (year)

< 0.001

 < 40

445 (11.4)

204 (13.8)

241 (10.1)

 40–60

2589 (67.0)

1028 (69.2)

1561 (65.5)

 > 60

834 (21.6)

253 (17.0)

581 (24.4)

Stage

< 0.001

 I

586 (15.1)

206 (13.9)

380 (15.9)

 II

1553 (40.1)

621 (41.8)

932 (39.1)

 III

831 (21.5)

275 (18.5)

556 (23.4)

 IV

265 (6.8)

97 (6.5)

168 (7.0)

Unknown

633 (16.4)

286 (19.2)

347 (14.6)

Chemotherapy

< 0.001

 No

1178 (30.4)

399 (26.9)

779 (32.7)

 Yes

2690 (69.5)

1086 (73.1)

1604 (67.3)

Chemotherapy Regimens

< 0.001

 CMF

161 (6.0)

142 (13.1)

19 (1.2)

 FAC/FEC/AC

1930 (71.7)

840 (77.4)

1090 (67.9)

 AC-T

599 (22.3)

104 (9.6)

495 (30.9)

Radiotherapy

   

0.03

 No

1794 (46.4)

722 (48.6)

1072 (45.0)

 Yes

2074 (53.6)

763 (51.4)

1311 (55.0)

Hormonal therapy

< 0.001

 No

1772 (45.8)

770 (51.8)

1002 (42.0)

 Yes

2096 (54.2)

715 (48.1)

1381 (58.0)

Hormonal therapy agent

< 0.001

 Tamoxifen

1335 (75.2)

583 (86.6)

752 (68.3)

 Aromatase Inhibitor

439 (24.8)

90 (13.4)

349 (31.7)

  1. CMF Cyclophosphamide, methotrexate, and fluorouracil; FAC Fluorouracil, anthracycline, and cyclophosphamide; FEC Fluorouracil, epirubicin, and cyclophosphamide; AC Anthracycline and cyclophosphamide; AC-T Anthracycline, cyclophosphamide, and taxane
  2. aChi-square test